title: CI 988, an antagonist of the cholecystokinin-B receptor, potentiates endogenous opioid-mediated antinociception at spinal level.
abstract: The effects of RB 101 {N-[(R, S)-2-benzyl-3[(S)(2-amino-4-methylthio)butyl dithio]-1-oxo-propyl]-L-phenylalanine benzyl ester}, a complete inhibitor of enkephalin-degrading enzymes and CI 988, a selective antagonist of the cholecystokinin (CCK)-B receptors, on the flexor reflex in decerebrate, spinalized, unanaesthetized rats were assessed. Intravenous RB 101 induced a dose-dependent depression of the flexor reflex with a threshold dose of 20 mg/kg and an ED50 of 25.3 mg/kg. Subcutaneous CI 988 at 1 mg/kg, which by itself did not influence the flexor reflex, strongly enhanced the reflex depressive effect of RB 101. The dose-response curve for RB 101 was shifted to the left and the duration of reflex depression was significantly prolonged. The results confirmed and extended previous behavioural data indicating that blockade of CCK-B receptors potentiated antinociception elicited by endogenous opioids protected from enzymatic degradation. Furthermore, the spinal cord is an important site of interaction between the endogenous opioid and CCK systems.
authors.affiliation: Department of Medical Laboratory Sciences and Technology, Karolinska Institute, Huddinge University Hospital, Sweden. Xiao-Jun.Xu@neurophys.hs.sll.se
authors.forename: X J
authors.initials: XJ
authors.lastname: Xu
authors.forename: A
authors.initials: A
authors.lastname: Elfvin
authors.forename: J X
authors.initials: JX
authors.lastname: Hao
authors.forename: M C
authors.initials: MC
authors.lastname: Fournié-Zaluski
authors.forename: B P
authors.initials: BP
authors.lastname: Roques
authors.forename: Z
authors.initials: Z
authors.lastname: Wiesenfeld-Hallin
mesh_terms: D000700:Analgesics / Q000494:pharmacology; D000818:Animals; D003655:Decerebrate State / Q000503:physiopathology; D004220:Disulfides / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D005260:Female; D006727:Hormone Antagonists / Q000494:pharmacology*; D007211:Indoles / Q000494:pharmacology*; D007275:Injections, Intravenous; D008536:Meglumine / Q000031:analogs & derivatives* / Q000494:pharmacology; D009619:Nociceptors / Q000187:drug effects; D018847:Opioid Peptides / Q000378:metabolism*; D010649:Phenylalanine / Q000031:analogs & derivatives / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D043887:Receptor, Cholecystokinin B; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors*; D012018:Reflex / Q000187:drug effects; D013116:Spinal Cord / Q000737:chemistry* / Q000187:drug effects
chemical_list: D000700:Analgesics; D004220:Disulfides; D006727:Hormone Antagonists; D007211:Indoles; D018847:Opioid Peptides; D043887:Receptor, Cholecystokinin B; D011949:Receptors, Cholecystokinin; C065599:PD 134308; C074024:RB 101; D010649:Phenylalanine; D008536:Meglumine